Anti-anginal agent is the latest drug to flop as an effective therapy remains elusive
Another fatty acid β-oxidation inhibitor failed to boost exercise capacity or ease symptoms in non-obstructive hypertrophic cardiomyopathy (HCM) in a small placebo-controlled trial.